Charles Schwab Investment Management Inc Rocket Pharmaceuticals, Inc. Transaction History

Charles Schwab Investment Management Inc

$557 Billion
Q2 2025

A detailed history of Charles Schwab Investment Management Inc transactions in Rocket Pharmaceuticals, Inc. stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 614,761 shares of RCKT stock, worth $1.97 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

614,761

Previous 675,481 8.99%

Holding current value

$1.97 Million

Previous $4.51 Million 66.57%

% of portfolio

0.0%

Previous 0.0%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 12, 2025	SELL	$2.33 - $8.01 $141,477 - $486,367	-60,720 Reduced 8.99%	614,761 $1.51 Million
Q1 2025 Sep 15, 2025	BUY	$6.67 - $12.72 $405,002 - $772,358	60,720 Added 9.88%	675,481 $4.51 Million
Q1 2025 May 09, 2025	BUY	$6.67 - $12.72 $129,337 - $246,653	19,391 Added 2.96%	675,481 $4.51 Million
Q4 2024 Feb 06, 2025	BUY	$11.35 - $18.82 $979,232 - $1.62 Million	86,276 Added 15.14%	656,090 $8.25 Million
Q3 2024 Nov 12, 2024	BUY	$17.6 - $25.88 $357,667 - $525,933	20,322 Added 3.7%	569,814 $10.5 Million
Q2 2024 Aug 12, 2024	BUY	$20.66 - $26.72 $349,753 - $452,342	16,929 Added 3.18%	549,492 $11.8 Million
Q1 2024 May 08, 2024	BUY	$26.16 - $30.74 $186,023 - $218,592	7,111 Added 1.35%	532,563 $14.3 Million
Q4 2023 Feb 06, 2024	BUY	$16.78 - $31.94 $960,587 - $1.83 Million	57,246 Added 12.23%	525,452 $15.7 Million
Q3 2023 Nov 08, 2023	BUY	$15.07 - $24.05 $494,838 - $789,705	32,836 Added 7.54%	468,206 $9.59 Million
Q2 2023 Aug 09, 2023	BUY	$16.59 - $23.6 $130,248 - $185,283	7,851 Added 1.84%	435,370 $8.65 Million
Q1 2023 May 11, 2023	BUY	$15.79 - $22.6 $84,381 - $120,774	5,344 Added 1.27%	427,519 $7.32 Million
Q4 2022 Feb 13, 2023	BUY	$15.5 - $22.76 $1.22 Million - $1.8 Million	78,911 Added 22.99%	422,175 $8.26 Million
Q3 2022 Nov 14, 2022	BUY	$12.37 - $18.41 $230,787 - $343,475	18,657 Added 5.75%	343,264 $5.48 Million
Q2 2022 Aug 15, 2022	BUY	$7.96 - $16.64 $11,422 - $23,878	1,435 Added 0.44%	324,607 $4.47 Million
Q1 2022 May 13, 2022	BUY	$13.16 - $23.68 $171,593 - $308,763	13,039 Added 4.2%	323,172 $5.13 Million
Q4 2021 Feb 11, 2022	BUY	$21.52 - $36.02 $146,960 - $245,980	6,829 Added 2.25%	310,133 $6.77 Million
Q3 2021 Nov 16, 2021	BUY	$27.42 - $48.97 $172,444 - $307,972	6,289 Added 2.12%	303,304 $9.07 Million
Q2 2021 Aug 16, 2021	BUY	$39.41 - $47.25 $616,214 - $738,801	15,636 Added 5.56%	297,015 $13.2 Million
Q1 2021 May 17, 2021	BUY	$43.34 - $65.91 $903,335 - $1.37 Million	20,843 Added 8.0%	281,379 $12.5 Million
Q4 2020 Feb 16, 2021	BUY	$23.3 - $59.57 $607,687 - $1.55 Million	26,081 Added 11.12%	260,536 $14.3 Million
Q3 2020 Nov 13, 2020	BUY	$20.5 - $28.59 $50,204 - $70,016	2,449 Added 1.06%	234,455 $5.36 Million
Q2 2020 Aug 14, 2020	BUY	$13.32 - $22.61 $312,407 - $530,294	23,454 Added 11.25%	232,006 $4.86 Million
Q1 2020 May 15, 2020	BUY	$9.71 - $25.11 $89,516 - $231,489	9,219 Added 4.62%	208,552 $2.91 Million
Q4 2019 Feb 07, 2020	BUY	$11.07 - $24.23 $125,600 - $274,913	11,346 Added 6.04%	199,333 $4.54 Million
Q3 2019 Nov 08, 2019	BUY	$10.85 - $14.78 $23,088 - $31,451	2,128 Added 1.14%	187,987 $2.19 Million
Q2 2019 Aug 09, 2019	BUY	$15.0 - $19.81 $598,755 - $790,755	39,917 Added 27.35%	185,859 $2.79 Million
Q1 2019 May 14, 2019	BUY	$13.45 - $19.01 $211,460 - $298,875	15,722 Added 12.07%	145,942 $2.56 Million
Q4 2018 Feb 14, 2019	BUY	$11.21 - $23.53 $67,484 - $141,650	6,020 Added 4.85%	130,220 $1.93 Million
Q3 2018 Nov 13, 2018	BUY	$18.5 - $25.49 $1.52 Million - $2.09 Million	81,901 Added 193.62%	124,200 $3.06 Million
Q2 2018 Aug 08, 2018	BUY	$14.58 - $23.0 $616,719 - $972,877	42,299 New	42,299 $831,000

Others Institutions Holding RCKT

# of Institutions

221

Shares Held

98.4M

Call Options Held

611K

Put Options Held

474K

View Full List

About ROCKET PHARMACEUTICALS, INC.

Ticker RCKT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 75,683,696
Market Cap $243M
Description
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells...

More about RCKT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Rocket Pharmaceuticals, Inc. Transaction History